Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Fovinaciclib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Fovinaciclib is an oral capsule for advanced breast cancer that is hormone receptor-positive and HER2-negative (HR+/HER2−). It is made in China by Jinzhou Avanc Pharmaceutical, a subsidiary of Fosun Pharma, and is sold there as 复妥宁®. Its Chinese name is 枸橼酸伏维西利胶囊 (fovinaciclib citrate capsules). It is always combined with a hormone (endocrine) medicine.
China's National Medical Products Administration (NMPA) approved it in May 2025 and added a first-line use in September 2025. It is approved for adults with HR+/HER2− locally advanced or metastatic breast cancer:
It can be used whether a woman is before, around or after menopause. It is a prescription cancer medicine and should only be used under a medical oncologist.
Hormone-sensitive breast cancer cells depend on two enzymes, CDK4 and CDK6, to move from resting to dividing. Fovinaciclib blocks both. Combined with hormone therapy, which cuts off the oestrogen signal that feeds the tumour, it holds back cancer growth for longer than hormone therapy alone. The company says its molecule was designed to reduce gut side effects and liver enzyme problems.
According to the Chinese prescribing information:
Capsules come in 100 mg and 25 mg strengths; the usual 200 mg dose is two 100 mg capsules. Treatment continues while it is helping and side effects are acceptable. Your oncologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Low blood counts: the label's pooled safety data from 464 patients show that drops in white cells, neutrophils and platelets, and anaemia, are the most common side effects (each in 20% or more). These are also the most common severe effects. Blood counts are checked regularly, and your doctor can pause or adjust treatment. Report fever, bruising or unusual tiredness straight away.
Overall: in the first-line trial, severe treatment-related side effects occurred in 85.1% on fovinaciclib and 14.4% on placebo, mostly low blood counts found on tests. Serious side effects were 14.4% vs 11.5%, and only 2 patients in each group stopped because of treatment-related side effects. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other targeted options in HR-positive advanced breast cancer, see our pages on Truqap and Itovebi.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each 28-day cycle uses 21 days of capsules, and we plan quantities cycle by cycle so the next supply arrives before the break ends. The capsules travel in their sealed original packs and are stored as directed on the pack, with temperature-controlled shipping to protect them in transit. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Oncology centres here treat breast cancer patients from across North India, and orders are dispatched from New Delhi.
We time each delivery to the 7-day break, so the next cycle can start on schedule.
Oncologists can request supply for a named patient and receive a written quote before ordering.
Patients in Chennai can have cycle-by-cycle supplies sent to the hospital or to home.
If the dose is reduced, we adjust the mix of 100 mg and 25 mg capsules to match the new prescription.
Deliveries to Kolkata and eastern India are tracked from dispatch to arrival.
Patients in Pune can use the same documented import route, with updates at each step.
The treating oncologist can begin the process by sending the prescription and receptor report.
Patients under treatment in Vellore can receive supplies directly at the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh on continuing oral therapy.
We arrange repeat deliveries for patients across Uttar Pradesh.
Patients across Kerala can receive their capsules in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
